The introduction of GLP-1-R agonists is also substantiated by The Diabetes, Cardiorenal, and Metabolism task force, which considers such drugs to be effective in primary and secondary stroke prevention in subjects with T2DM [69]. The gene discussed is GLP1R; the disease is stroke disorder.